A spinal cord stimulator (SCS) is an implanted device that delivers mild electrical impulses to the spinal cord to interrupt pain signals before they reach the brain. It is a pain-management approach — not a structural repair. For patients whose pain stems from an identifiable disc tear or herniation, a clinical evaluation to explore biologic disc repair options is the appropriate first step.

What Is a Spinal Cord Stimulator?

A spinal cord stimulator is an implantable neuromodulation device consisting of a pulse generator — similar in concept to a cardiac pacemaker — and one or more thin electrode leads placed in the epidural space near the spinal cord. The device generates low-level electrical current that disrupts pain signal transmission along nerve pathways, reducing the perception of pain in targeted areas of the body.

SCS is classified as a neuromodulation therapy: it modifies nerve activity rather than correcting anatomical problems. This distinction is clinically significant. SCS does not heal disc tears, decompress compressed nerves, or reverse scar tissue formation. It changes how pain signals are processed and perceived. Patients who have an identifiable structural source of pain — such as an annular tear or disc herniation — are evaluated to determine whether structural repair options remain viable before considering a permanently implanted device.

How Does a Spinal Cord Stimulator Work?

The mechanism underlying SCS is rooted in the gate control theory of pain, first proposed by Melzack and Wall in 1965. This theory holds that non-painful stimuli — touch, vibration, electrical impulses — can effectively close the gate on pain signal transmission in the dorsal horn of the spinal cord, reducing the signal that reaches the brain.

Modern SCS devices operate through several overlapping mechanisms:

• Paresthesia-based stimulation: Traditional SCS delivers a mild tingling sensation in the painful area that competes with pain signals.
• High-frequency stimulation (HF10): Delivers 10,000 Hz pulses below the paresthesia threshold, providing pain relief without the tingling sensation.
• Burst stimulation: Mimics patterns of natural neural activity to modulate pain processing at the thalamic level.
• Dorsal root ganglion (DRG) stimulation: Targets specific nerve roots for focal pain patterns — foot, groin, knee — that traditional SCS addresses less precisely.

In all modes, the effect is signal modification, not structural correction. The underlying condition causing pain remains unchanged after SCS implantation.

Who Is a Candidate for a Spinal Cord Stimulator?

SCS is most appropriate for patients with chronic neuropathic pain that has not responded to conservative care and where no surgically or biologically addressable structural source remains. A clinical evaluation is the only way to know for certain whether SCS is appropriate for any individual patient.

SCS is most commonly considered for:

• Failed back surgery syndrome (FBSS): Persistent pain after one or more spinal surgeries, particularly when scar tissue, nerve damage, or altered spinal mechanics are the likely cause. Back surgery carries roughly a 40% failure rate based on peer-reviewed FBSS literature, creating a substantial population of patients with post-surgical pain. For many of these patients, biologic disc repair options warrant evaluation before committing to permanent hardware — among patients with FBSS who received intra-annular fibrin injection, 80% reported positive outcomes (outcome registry data; individual outcomes vary).
• Complex regional pain syndrome (CRPS) Types I and II: Chronic neuropathic conditions with diffuse, burning pain that does not respond to other therapies.
• Refractory neuropathic pain: Radiculopathy or peripheral neuropathy that has not responded to medications, injections, or physical therapy.
• Post-fusion pain without a mechanical correction target: Pain persisting after spinal fusion when adjacent segment disease or nerve sensitization — rather than a structurally addressable source — is the dominant problem. Learn more about adjacent segment disease and its implications after fusion.

SCS is generally not the first-line recommendation for patients with an identifiable, untreated structural source of pain — such as an active annular tear or contained disc herniation — where biologic repair approaches remain viable. For those patients, evaluating spine repair options that address the structural source without implanting permanent hardware is the appropriate first step.

What Does the SCS Procedure Involve?

Before permanent implantation, patients undergo a trial period — typically seven days — with a temporary external device. Electrode leads are placed percutaneously through small needles and connected to an external pulse generator worn outside the body. The trial is fully reversible: leads are removed in a brief office procedure if the trial is unsuccessful. The standard clinical threshold for proceeding to permanent implant is at least 50% pain relief during the trial period.

The trial is the most important safeguard in the SCS process. Patients who do not meet the 50% threshold during the trial are not candidates for permanent implantation. This staged approach reduces the risk of committing to permanent hardware that does not provide meaningful relief.

If the trial is successful, permanent implantation involves a brief surgical procedure under general or regional anesthesia to place the pulse generator — typically in the upper buttock or lower abdomen — and secure the leads. The procedure is performed in an ambulatory surgical setting in most cases.

What Are the Risks and Limitations of a Spinal Cord Stimulator?

SCS is an established therapy with a meaningful evidence base for appropriate indications. It also carries risks that patients should understand before proceeding. Limitations and risks include:

• Lead migration: Electrode leads can shift position, altering or eliminating stimulation coverage and potentially requiring revision.
• Hardware failure: Pulse generators and leads are mechanical devices subject to failure over time. Battery replacement or device revision may be required.
• Infection: Any implanted hardware carries infection risk, which can necessitate device removal.
• Diminishing effect over time: Some patients experience reduced efficacy as the nervous system adapts to the stimulation pattern.
• MRI compatibility limitations: Older SCS systems are not fully MRI-compatible. Newer systems have improved MRI compatibility, but restrictions vary by device and field strength.
• No structural repair: The underlying disc pathology, scar tissue, or nerve damage that created the pain condition is not addressed by SCS. Patients with untreated structural sources of pain who proceed to SCS without first exploring repair options may miss an opportunity to address the root cause.

How Does SCS Compare to Biologic Disc Repair for Disc-Related Pain?

For patients whose chronic pain originates from an identifiable disc tear or herniation, SCS and biologic disc repair represent fundamentally different strategies. SCS manages pain signals; biologic disc repair — such as intra-annular fibrin injection — is designed to seal the annular tear and support the disc’s natural healing process.

Among patients tracked over long-term follow-up, the fibrin procedure showed a 83% success rate across more than 7,000 procedures with long-term data (outcome registry; individual outcomes vary). VAS pain scores in fibrin studies moved from 72.4 mm at baseline to 33.0 mm at 104 weeks (peer-reviewed fibrin outcome study; individual outcomes vary). These are population-level statistics — a clinical evaluation is the only way to determine which approach is appropriate for a given patient.

For patients who have already undergone spinal surgery without adequate relief, exploring whether disc-level pathology remains addressable is a critical step before committing to a pain management implant. Resources for evaluating this path include:

• What Is Failed Back Surgery Syndrome? Causes, Symptoms, and Recovery Options
• How to Evaluate Non-Surgical Disc Repair When Surgery Failed
• 80% Pain Reduction After Failed Fusion: How a Retired Construction Worker Recovered with Intra-Annular Fibrin Injection

Frequently Asked Questions About Spinal Cord Stimulators

Is a spinal cord stimulator a permanent solution?

SCS is a long-term pain management tool, not a cure. The device remains implanted and may require battery replacement or revision over time. The underlying condition causing pain is not repaired by SCS. Individual outcomes vary significantly.

Does a spinal cord stimulator work for disc herniation or annular tears?

SCS is not designed to repair disc herniation or annular tears. It modifies how pain signals are perceived. For patients with active disc pathology, a clinical evaluation to determine whether biologic repair options remain viable is the appropriate first step before considering an implanted device.

What is the success rate of a spinal cord stimulator?

Success rates vary by indication and by how success is defined. The 50% pain relief threshold during the trial period is the standard clinical benchmark for proceeding to permanent implantation. Long-term efficacy data varies by patient population and pain type. A clinical evaluation provides the most accurate picture of expected outcomes for a specific patient’s situation.

Can a spinal cord stimulator be removed?

The trial phase leads are fully removable. Permanent hardware can be surgically removed, but removal carries the risks associated with any surgical procedure and may leave residual tissue changes. The decision to implant permanent hardware should be made carefully and after exhausting appropriate alternatives.

Who is not a good candidate for a spinal cord stimulator?

Patients with an untreated, structurally addressable source of pain — such as an active annular tear or contained disc herniation — are not typically candidates for SCS as a first approach. Patients with active infections, certain bleeding disorders, or psychological conditions that have not been treated may also not be appropriate candidates. A clinical evaluation is the only way to determine candidacy with certainty.

Is intra-annular fibrin injection an alternative to a spinal cord stimulator?

For patients whose pain originates from disc-level pathology — annular tears, disc herniation — the fibrin procedure is designed to address the structural source, which is a different goal than SCS’s signal-modification approach. Whether fibrin disc repair is an option depends on a clinical evaluation including imaging review. A clinical evaluation is the only way to know for certain which approach fits a patient’s specific condition.

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified physician. Treatment decisions depend on your individual medical history and clinical findings. Schedule a consultation to discuss whether the procedure is right for you.